Abstract P5-14-02: Time to treatment discontinuation as a pragmatic endpoint: A U.S. Food and Drug Administration pooled analysis of CDK 4/6 inhibitors
Gao, JJ, Gong, Y, Cheng, J, Schroeder, RJ, Amiri-Kordestani, L, Khozin, S, Kluetz, P, Sridhara, R, Pazdur, R, Blumenthal, G, Beaver, JA, Prowell, TM
Published in Cancer research (Chicago, Ill.) (15.02.2019)
Published in Cancer research (Chicago, Ill.) (15.02.2019)
Get full text
Journal Article
Abstract P5-17-01: A definition of a high-risk early-breast cancer population based on data from the collaborative trials in neoadjuvant breast cancer (CTNeoBC) meta-analysis
Cortazar, P, Zhang, L, Untch, M, Mehta, K, Constantino, J, Wolmark, N, Bonnefoi, H, Piccart, M, Gianni, L, Valagussa, P, Zujewski, JA, Justice, R, Loibl, S, Swain, SM, Bogaerts, J, Baselga, J, Prowell, TM, Rastogi, P, Sridhara, R, Tang, S, Pazdur, R, Mamounas, E, von Minckwitz, G
Published in Cancer research (Chicago, Ill.) (15.12.2013)
Published in Cancer research (Chicago, Ill.) (15.12.2013)
Get full text
Journal Article
Lipophilic statins merit additional study for breast cancer chemoprevention
Prowell, Tatiana M, Stearns, Vered, Trock, Bruce
Published in Journal of clinical oncology (01.05.2006)
Published in Journal of clinical oncology (01.05.2006)
Get full text
Journal Article